Dr Henry Moss is a Researcher at the Department of Applied Mathematics and Theoretical Physics within the School of Physical Sciences at the University of Cambridge. His work focuses on machine learning applications in climate modeling, Bayesian optimization, and Gaussian processes, bridging computational mathematics with environmental science and chemistry. His research interests include: Bayesian optimization for environmental and chemical systems Reinforcement learning in climate modeling Gaussian processes for molecular property prediction High-throughput machine learning in scientific domains Interpretable AI for coastal flooding prediction Hybrid ML-physics modeling Dr Moss's publications highlight his contributions to federated learning for climate models, sparse Gaussian process techniques, and multi-objective optimization frameworks. These works span applications in weather prediction, chemical engineering, and oceanography. Email: hwm26@cam.ac.uk
Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.
Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.
Andy Pavlo is an Associate Professor with Indefinite Tenure in the Computer Science Department at Carnegie Mellon University's School of Computer Science. He is an active member of the CMU Database Group and the Parallel Data Laboratory, where he leads research in database management systems with a focus on self-driving architectures, transaction processing, and large-scale analytics. His work bridges academic research and industry applications through projects like NoisePage, OtterTune (which he co-founded and served as CEO before it ceased operations), and Peloton. Dr. Pavlo's research interests span database management systems with particular emphasis on autonomous database architectures that can self-tune and optimize without human intervention. His work explores transaction processing systems that can handle high-throughput workloads while maintaining consistency, and large-scale data analytics techniques that efficiently process massive datasets. He has made significant contributions to query optimization, database extensibility, and automatic database tuning using machine learning techniques. His recent work on database extensibility revealed critical issues in PostgreSQL's extension ecosystem, showing that approximately 16% of extensions are incompatible with at least one other extension due to API violations and memory errors. His research output demonstrates a consistent focus on practical database systems challenges, with recent publications examining database extensibility, user-defined function optimization, and the cyclical nature of database research. The articles show a strong trend toward making database systems more autonomous, with increasing integration of machine learning techniques for automatic tuning and optimization. His work often combines deep theoretical analysis with practical implementation in open-source systems. Dijkstra Award 2024 for contributions to database systems research Dr. Pavlo actively mentors graduate students, with current advisees including Wan Shen Lim, William Zhang, and Sam Arch (co-advised with Todd Mowry). His former students have gone on to successful careers in both industry and academia. He has secured significant research funding through CMU's affiliate program with major database companies including ClickHouse, DataStax, dbt, Firebolt, MotherDuck, RelationalAI, SingleStore, Spiral, PingCAP/TiDB, Yellowbrick, and Yugabyte. His research is supported by these industry partnerships and likely includes NSF funding given his active participation in the database research community. At CMU, Dr. Pavlo leads the Database Group and organizes several seminar series including "SQL or Death," "Database Building Blocks," and "ML⇄DB Technical Talks." These seminars bring together researchers and practitioners to discuss cutting-edge developments in database systems. He also runs a summer research internship program that has attracted students for multiple consecutive years, indicating a strong research group with ongoing projects and funding.
Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award
Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.
David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.
Connor Coley is the Henri Slezynger (1957) Career Development Assistant Professor at the Massachusetts Institute of Technology (MIT) School of Engineering. His research bridges chemistry and machine learning, focusing on autonomous molecular discovery, predictive chemistry, and laboratory automation. Education: Ph.D., MIT (2019) M.S.CEP., MIT (2016) B.S., Caltech (2014) Research Interests: Dr. Coley’s work centers on domain-informed machine learning for chemistry, computer-aided molecular design, and autonomous laboratories. Key themes include predictive modeling of chemical reactivity, optimization of synthesis pathways, and integration of AI with experimental data for drug discovery and materials science. Publications: His recent articles highlight advancements in AI-driven reaction prediction, molecular representation learning, and laboratory automation. Trends include applications of Bayesian optimization, contrastive learning, and diffusion models to chemical discovery. Scientific Awards: Camille Dreyfus Teacher-Scholar Award (2025) James W. Swan Outstanding Faculty (2025) Schmidt Futures AI2050 Early Career Fellow (2022) NSF CAREER Award (2021) Forbes 30 Under 30: Healthcare (2019) Software & Tools: He leads the open-source ASKCOS software suite for synthesis planning, adopted by 35,000+ chemists and deployed at 15+ pharmaceutical companies. His team also develops tools for metabolomics and molecular representation learning.
Dr. Mihai Pop is a Professor of Computer Science and Director of the University of Maryland Institute for Advanced Computer Studies (UMIACS). He holds appointments in the Department of Computer Science, UMIACS, and the Center for Bioinformatics and Computational Biology (CBCB). His research focuses on computational biology, metagenomics, and algorithm development for genomic data analysis. He received a Ph.D. in Computer Science from Johns Hopkins University (2000), followed by work at The Institute for Genomic Research (TIGR) developing genome assembly algorithms. Education: Ph.D., Computer Science, Johns Hopkins University, 2000. Research Interests: Bioinformatics, genomics, metagenomics, computational geometry, software testing. His lab develops tools for analyzing microbial communities and has pioneered methods for metagenomic assembly and analysis. Notable tools include the AMOS genome assembly toolkit. Recent Article Trends: Recent work emphasizes long-read sequencing, metagenomic profiling (e.g., TIPP3), and strain-level analysis (e.g., Strainy). He addresses challenges in scaling sequence-based searches and improving taxonomic resolution in large datasets. Awards: ACM Fellow (2019), ISCB Fellow (2022), UMD Excellence in Teaching Award (2015). Grants & Leadership: Co-leader of the Human Microbiome Project data analysis group. Active in diversity initiatives to promote inclusivity in computational fields. Labs/Teams: Pop Lab (pop-lab.org) focuses on computational methods for microbial genomics and metagenomics.
Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.
Mariano Scazzariello is a Lecturer at KTH Royal Institute of Technology, Sweden, affiliated with the School of Electrical Engineering and Computer Science and the Department of Network and Systems Engineering. He teaches the course 'Network Systems with Edge or Cloud Datacenters (IK2227)'. His research focuses on advanced networking topics including machine learning in networks, high-speed packet processing, network emulation, and software-defined networking innovations. His work spans contributions to network emulation tools like Kathará and Megalos, stateful packet processing at terabit scales, and leveraging large language models (LLMs) for network configuration and vulnerability detection. Recent research emphasizes low-latency protocols (e.g., SRv6/DetNet integration) and GPU-centric networking on commodity hardware. Mariano’s publications (2020–2025) highlight expertise in network function virtualization, ASIC-based switching, and optimizing network configurations through AI-driven approaches. He has pioneered frameworks for evaluating routing protocols and virtualizing large network scenarios at scale.
Qiaowei Pan is a Researcher at the University of Lausanne , focusing on Evolution and Ecology . They have held a Guest Researcher role at the Institute of Molecular Biology gGmbH (IMB) in Mainz, Germany since 2023, and a Postdoctoral Researcher position at the University of Lausanne since 2018. Education: PhD in Molecular and Evolutionary Biology (2014-2018), INRAe, University of Rennes II, France Erasmus Mundus Master in Evolutionary Biology (MEME) (2012-2014), University of Groningen (Netherlands) & University of Montpellier II (France) BSc in Biology (2008-2012), University of North Carolina-Chapel Hill, USA Research Interests: Qiaowei Pan's work centers on the intersection of molecular genetics , evolutionary biology , and developmental biology , particularly in sex determination mechanisms across diverse animal models. Their studies span non-coding RNA regulation , sex chromosome evolution , and signal transduction pathways like TGF-β in reproductive systems. Publication Trends: Recent articles highlight expertise in sex determination systems (5/12 publications), genomic approaches (6/12), and fish developmental evolution . Collaborative work includes computational methods ( RADSex workflow ) and comparative studies across ant , goldfish , catfish , and cavefish models. Labs & Teams: Currently affiliated with the Keller-Valsecchi group at IMB and the Department of Evolution and Ecology at the University of Lausanne.
Prof. Hayden Kwok Hay SO is an Associate Professor at the University of Hong Kong (HKU), affiliated with the Department of Electrical and Electronic Engineering. He currently serves as Acting Director of the School of Innovation and previously co-directed the Computer Engineering Program. His research focuses on reconfigurable computing systems, FPGA-based architectures, and their applications in AIoT, medical imaging, and high-performance computing. He holds a B.S., M.S., and Ph.D. in Electrical Engineering and Computer Sciences from UC Berkeley (1998–2007). Prof. So has been recognized with awards such as the IEEE-HKN Teaching Award (2021), Croucher Innovation Award (2013), and multiple teaching excellence awards. He leads the Computer Architecture & System Research Lab (CASR) and co-founded the Joint Lab on Future Cities (JLFC). His work spans FPGA overlay architectures, graph processing systems, and hardware-software co-design for efficient computing. Key research contributions include advancements in FPGA-based reconfigurable systems, sparse dataflow architectures, and medical imaging accelerators. He has secured grants for projects like 'Advanced machine vision guided aquatic surface vehicles' and 'Efficient and Productive Parallel Data Processing in Hybrid FPGA-CPU Clusters.' Prof. So has advised numerous students and researchers, contributing to over 150 peer-reviewed publications. His current projects explore AI hardware acceleration, neuromorphic computing, and FPGA-driven solutions for big data challenges.
James C. Hoe is Professor of Electrical and Computer Engineering at Carnegie Mellon University (College of Engineering). He is on sabbatical at MangoBoost and directs research in computer architecture, reconfigurable computing, and high-level hardware design. Education Ph.D., Electrical Engineering and Computer Science, MIT (2000) M.S., Electrical Engineering and Computer Science, MIT (1994) B.S., Electrical Engineering and Computer Science, UC Berkeley (1992) Research Interests Professor Hoe’s work spans computer architecture , reconfigurable computing , FPGA architectures , and high-level hardware synthesis . His group created the CoRAM abstraction for virtualized FPGA computing and leads efforts in power-efficient accelerators, in-network computing, and security-oriented FPGA systems. Scientific Awards IEEE Fellow (2013) Intel Outstanding Researcher Award (2021) Research Funding & Projects Intel / VMware Crossroads 3D-FPGA Academic Research Center – co-leading exploration of FPGA roles in future datacenters. DARPA BRASS program ($2.7 M, 4 years) – ensuring long-lived software systems remain robust to resource changes. Pigasus open-source IDS – world’s fastest FPGA-accelerated intrusion-detection system (100 Gb/s on one server). Labs & Teams He heads activities within the Computer Architecture Lab at Carnegie Mellon (CALCM) , supervising graduate researchers on CoRAM++, SPIRAL autotuning, and FPGA overlays for stream processing.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
